FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
93 letters match. Newest first.
-
DrugsNatural Essentials, Inc.
FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.
High risk -
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsSnugZ USA, Inc.
SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsTianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
High risk -
DrugsAlmon Healthcare Private Limited
Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.
High risk -
DrugsShimoga Chemicals
FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
High risk -
DrugsGopaldas Visram & Co., Ltd.
FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsUmendra Life Sciences Private Limited
Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.
High risk -
DrugsAsanuma Corporation - Sagamihara Factory
FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.
High risk -
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsHangzhou Yiqi Biotechnology Co., Ltd
FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.
High risk -
DrugsIDO Pharm Co., Ltd.
IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.
High risk -
DrugsActive Cosmetics Manufacturing Inc.
FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.
High risk -
DrugsRespilon Production S.R.O.
FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.
Medium -
DrugsPro Numb Tattoo Numbing Spray, LLC
FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.
High risk -
DrugsPatcos Cosmetics Pvt. Ltd.
Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.
High risk -
DrugsFlowchem Pharma Private Limited
FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.
High risk -
DrugsCosmetic Manufacturers Pty Ltd.
FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.
High risk -
DrugsAbsolutely Natural
FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.
High risk -
DrugsTower Laboratories Ltd.
FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.
High risk -
DrugsSV Labs Corporation
SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.
High risk -
DrugsOwen Biosciences, Inc.
Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.
High risk -
DrugsCdymax India Pharma Private Limited
FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.
High risk -
DrugsGuangxi Yulin Pharmaceutical Group Co. Ltd.
FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.
High risk -
DrugsCreative Essences, Inc.
FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.
High risk -
DrugsAnhui Hanbon Daily Chemical Co., Ltd.
FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.
High risk -
DrugsGlenmark Pharmaceuticals Limited
FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.
High risk -
DrugsHealwell Homeo Private Limited
FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
High risk -
DrugsAmish Origins Management, LLC
FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.
High risk -
DrugsCTK OTC Laboratories LLC formerly FMK LABS, Inc.
CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.
High risk -
DrugsHuangshi Hygienic Material Medicine Co., Ltd.
Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.
High risk -
DrugsTaizhou Jingshang Cosmetics Technology Co., Ltd.
FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.
High risk -
DrugsBEO Pharma Inc. dba BEO Pharmaceuticals Inc.
FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.
High risk -
DrugsABR Laboratory LLC
FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
High risk -
DrugsJagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.
High risk -
DrugsWuhu Nuowei Chemistry Co., Ltd.
FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
High risk -
DrugsStrukmyer LLC dba Strukmyer Medical
Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsBrands International Corporation
Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.
High risk -
DrugsMicro Orgo Chem
Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.
High risk -
FoodWANABANA USA LLC
WanaBana USA LLC failed to verify foreign supplier safety for lead-contaminated apple cinnamon puree pouches.
High risk -
DrugsMultaler et Cie SAS
FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.
High risk -
DrugsAnalytical Food Laboratories, Inc.
FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.
High risk -
DrugsMMC Healthcare Ltd.
FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.
High risk -
DrugsGuangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.
FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.
High risk -
DrugsLaboratorio Magnachem International
FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.
High risk -
DrugsTCT Nutraceuticals SDN. BHD
FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.
High risk